|
Originally published In Press as doi:10.1074/jbc.M110750200 on April 23, 2002
J. Biol. Chem., Vol. 277, Issue 26, 23949-23957, June 28, 2002
Activation of c-Raf Kinase by Ultraviolet
Light
REGULATION BY RETINOIDS*
Beatrice
Hoyos,
Asiya
Imam,
Irina
Korichneva,
Ester
Levi,
Ramon
Chua, and
Ulrich
Hammerling
From the Immunology Program, Memorial Sloan-Kettering Cancer
Center, New York 10021
Received for publication, November 8, 2001, and in revised form, April 17, 2002
 |
ABSTRACT |
The present study highlights retinoids as
modulators of c-Raf kinase activation by UV light. Whereas a number of
retinoids, including retinol, 14-hydroxyretroretinol, anhydroretinol
(AR), and retinoic acid bound the c-Raf cysteine-rich domain (CRD) with equal affinity in vitro as well as in vivo,
they displayed different, even opposing, effects on UV-mediated kinase
activation; retinol and 14-hydroxyretroretinol augmented responses,
whereas retinoic acid and AR were inhibitory. Oxidation of thiol groups
of cysteines by reactive oxygen, generated during UV irradiation, was
the primary event in c-Raf activation, causing the release of zinc ions
and, by inference, a change in CRD structure. Retinoids modulated these oxidation events directly: retinol enhanced, whereas AR suppressed, zinc release, precisely mirroring the retinoid effects on c-Raf kinase
activation. Oxidation of c-Raf was not sufficient for kinase activation, productive interaction with Ras being mandatory. Further, canonical tyrosine phosphorylation and the action of phosphatase were
essential for optimal c-Raf kinase competence. Thus, retinoids bound
c-Raf with high affinity, priming the molecule for UV/reactive oxygen
species-mediated changes of the CRD that set off GTP-Ras interaction
and, in context with an appropriate phosphorylation pattern, lead to
full phosphotransferase capacity.
 |
INTRODUCTION |
The c-Raf proto-oncogene is essential for cell growth,
differentiation, and survival. Its major downstream effector is the mitogen-activated protein kinase
(MAPK)1 (1, 2) that elicits a
complex set of cytosolic (3-5) as well as nuclear signals (6-9). The
molecular mechanism of c-Raf activation has not yet been fully
elucidated (for reviews, see Refs. 10 and 11). That growth factors and
cytokines, as well as UV and ionizing radiation, all lead to the
activation of the c-Raf/MAPK pathway has been amply demonstrated
(12-15). Receptor protein tyrosine kinase, ligated by their
respective growth factors, dimerize, become autophosphorylated, and
recruit adapter molecules (Grb2) and the nucleotide exchange factor SOS
to the cell membrane. The further assembly of GTP-bound Ras enables
c-Raf to translocate from the cytosol to the plasma membrane, where an
as yet unidentified mechanism bestows competence on c-Raf to activate
the MAPK cascade (16). Phosphorylation of tyrosine residues
(e.g. Tyr-340 and Tyr-341 (17)) and dephosphorylation of
serine residues (Ser-259 and Ser-621 (18)) are believed to lock c-Raf
into the optimally competent form.
For docking with Ras, two important contact sites in the regulatory
domain of c-Raf have been identified, one centered on the stretch of
amino acids 51-131, the other contained within the CRD (19, 20). What
remains to be identified is the initial molecular event that triggers
cytosol-to-membrane translocation. Whether this involves changes in the
phosphorylation pattern and consequent changes in the conformation of
the regulatory domain is still unclear. The participation of lipid
mediators in the activation of c-Raf has been suspected because of
structural similarities with the PKC family of serine/threonine kinases
(21, 22), which harbor lipid binding sites in their CRD tandem repeats
(23-25). Bound phosphatidylserine enhanced PKC activity (26). Several groups have identified lipid binding sites in the regulatory and catalytic regions of c-Raf (27-30). Interestingly, Romero and
colleagues (30) suggested that phosphatidic acid mediated c-Raf
translocation from cytoplasm to membrane independently of its
association with Ras.
Besides the classical RTPK signal chain, alternative activation signals
exist. Ultraviolet light and ionizing irradiation as well as oxidizing
agents lead to c-Raf/MAPK activation (13-15). To understand the
biological significance, it is worth remembering that macrophages
naturally produce substantial concentrations of hydrogen peroxide and
that reactive oxygen species (ROS) are produced in every cell
type by mitochondria as well as by dedicated enzyme systems. The
changing view is that ROS, like nitric oxide, serve as normal
intracellular messengers (31-34). Also long known, the potent
activating capacity of ultraviolet irradiation rests on the
intracellular production of ROS (35, 36).
Whereas the chemistry of oxidative activation of serine/threonine
kinases is poorly understood, it stands to reason that ROS target the
most susceptible groups in c-Raf, namely the thiols of cysteines,
assuming a direct chemical modification and not activation of an
upstream factor. Direct attack by ROS is all the more likely, since six
cysteine residues are clustered within a stretch of 50 amino acids of
the regulatory domain, all susceptible to oxidation. The questions of
what changes the CRD may undergo during UV activation and how retinoids
regulate such chemical changes are addressed in the present report. If
the biology of vitamin A were a guide (37-40), the expectation would
be that hydroxylated retinoids (retinol and 14HRR) enhanced, whereas
anhydroretinol attenuated, the UV effects. This prediction was
borne out.
As previously shown, vitamin A functions as regulatory co-factor for
redox regulation of c-Raf and other serine/threonine kinases (41, 42).
A single site capable of binding several natural vitamin A metabolites
at nanomolar affinity was mapped to the CRD. Since bound retinoids
influenced redox activation (42), the importance of this domain as a
primary target for oxidation was suggested. Further, two zinc
coordination centers exist per CRD, each composed of three thiol groups
of cysteines and one imino group of histidine. Chemistry predicts that
oxidation of one or more thiols would compromise the integrity of the
zinc finger. Precedents that zinc finger structures serve as redox sensors of enzymes exist in bacteria, and the related structures in PKC
have recently been shown to shed their bound Zn2+ ions as a
result of oxidation (43).2 We
therefore asked whether Zn2+ ions would be liberated from
the c-Raf CRD during UV irradiation and whether pro-oxidant retinoids
would impact on zinc release.
We further investigated whether UV-mediated oxidation of the CRD was
per se sufficient for kinase activation but found that, unlike PKC and isoforms (42, 43), c-Raf required the additional productive interaction with GTP-bound Ras, as well as modifications in
the tyrosine and serine/threonine phosphorylation patterns. Nevertheless, the CRD emerged as the key target structure for ROS
elicited by stress-related mechanisms. Several findings in this report
will highlight our conclusion: the triggering of c-Raf activity by ROS
generated during UV irradiation in vitro; the binding of
pro-oxidant retinoids to the CRD; the conversion of thiol groups to
disulfide by UV exposure in vivo; the release of
Zn2+ ions after UV irradiation; and the requirement for the
CRD to communicate with Ras. Therefore, despite its appearance as a
rigid structural element, the CRD should be more appropriately viewed as a dynamic, redox-sensitive hinge with profound regulatory importance for initiation of the c-Raf activation cycle by UV light.
 |
MATERIALS AND METHODS |
Retinoids--
All-trans isomers of AR and 14HRR were
synthesized as described previously (37, 44). trans-Retinol
and RA were purchased from Sigma and purified by high pressure liquid
chromatography. [3H]Retinol was purchased from
PerkinElmer Life Sciences.
Immunological Reagents and Chemicals--
Anti-FLAG®
M2-agarose affinity gel, herbimycin A, okadaic acid, vanadate, and
perillic acid were obtained from Sigma. Rabbit antibody to the c-Raf
C-terminal peptide was purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA), and
N-(6-methoxy-8-quinolyl)-p-toluene-sulfonamide (TSQ) and 4-acetamido-4'-maleimidylstilbene 2,2'-disulfonic acid (AMS)
were obtained from Molecular Probes, Inc. (Eugene, OR). Digitonin was
bought from Fisher.
Plasmids--
FLAG-c-Raf was a gift from Dr. Roger J. Davis
(University of Massachusetts, Worcester, MA). N17-Ras was obtained from
Dr. N. M. Nathanson (University of Washington, Seattle, WA).
glutathione S-transferase (GST)- and FLAG-human c-Raf CRD
(136LTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLL195;
this peptide contains the natural Trp-186 residue, responsible for fluorescence emission) were constructed as previously described (41). The FLAG-c-Raf chimera was constructed by replacing the c-Raf CRD
with the PKC CRD. The following primers were used to isolate the
PKC CRD cDNA by polymerase chain reaction (template kindly
provided by Dr. T. Powell, Memorial Sloan-Kettering Cancer Center, New
York): 5'-CAT GTT CCC CTC ACA ACA CAC AAG TTC AAA ATC CAC and 5'-GAT
GTT ACT CCA GTC CAC GCA GAG GCT GGG GAC ATT GAT. This product was used
to synthesize the N and C termini of c-Raf chimeric gene using the
following primers: 5'-GCG GCC GCG AAT TCA ATG GAG CAC ATA CAG and
5'-TGA AGA CAG GTG GGA TCC TTA CTA GAA GAC AGG CAG CCT, respectively.
The two products were used to generate the full-length molecule by PCR,
which was then cloned into the EcoRI/BamHI sites
of the Sigma vector pFLAG-CMV2. Fidelity was confirmed by sequencing.
Transfection and UV Activation--
COS-7 cells were transfected
according to the calcium phosphate method (45). Briefly, 5 × 105 cells were plated in 60-mm dishes the day before
transfection. 2 h prior to transfection, the medium was replaced
with fresh growth medium (Dulbecco's modified Eagle's medium (high
glucose) supplemented with 10% fetal calf serum). 12 µg of DNA/dish
were mixed with CaCl2 and phosphate buffer to form a fine
precipitate, which was then dispersed over the cells. The day after
transfection, the medium was removed and the cells were washed twice
with 3 ml each of phosphate-buffered saline (PBS). The cells were
cultured with 2 ml of retinoid-free, phenol red-free Dulbecco's
modified Eagle's medium (high glucose) for 2 1/2 days prior to
activation. UV irradiation was performed for 2 min at 400 milliwatts/cm2 using the 312-nm wavelength. Cultures were
incubated at 37 °C for 10 min after irradiation and harvested.
c-Raf Immunoprecipitation/Kinase Assay--
Cells were lysed in
100 µl lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM EGTA, 1%
Triton X-100, 25 µg/ml each leupeptin and aprotinin, 30 mM -glycerophosphate, 30 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 1 mM
vanadate). The lysates were precleared with 30 µl of a 50% (v/v)
protein G-agarose slurry, and the FLAG-c-Raf protein was precipitated
using 30 µl of anti-FLAG M2 affinity gel (Sigma). The
immunoprecipitates were washed four times with lysis buffer containing
0.5 M NaCl and twice with kinase buffer (30 mM
Tris-HCl, pH 7.5, 10 mM MgCl2, 0.5 mM EGTA, and 1 mM vanadate). The kinase
reaction was performed in 20 µl of kinase buffer using 200 ng of
kinase-disabled His-MEK (K97M) (provided by Dr. R. Kolesnick, Memorial
Sloan-Kettering Cancer Center) as substrate, 60 mM ATP,
and 10 mCi of [ -32P]ATP (6,000 Ci/mmol). The reaction
was carried out for 20 min at 30 °C and terminated by the addition
of 10 µl of 4× Laemmli buffer (46). After separation by SDS-PAGE on
7.5% gels, the proteins were transferred to polyvinylidene
difluoride membrane and subjected to autoradiography, followed
by Western analysis. Both Western blot and autoradiographs were
evaluated by densitometry (Bio-Rad GS 700 densitometer with Quantity
One software). Kinase activity values were normalized for the amount of
FLAG-c-Raf precipitated. Data were analyzed by Student's t test.
AMS Trapping of Free Thiols in Vivo--
COS cells transfected
with FLAG-c-Raf CRD were UV-irradiated, treated with 1 or 10 mM H2O2, or left untreated and
incubated at 37 °C for 10 min. The medium was removed, cells were
washed with PBS, and 150 µl of 100 mM iodoacetamide in
permeabilization buffer (lysis buffer containing 20 µg/ml digitonin
instead of 1% Triton X-100) (47) were added. After incubation for 10 min at 37 °C, the reaction was terminated by the addition of 1%
Triton X-100, and cells were frozen in liquid nitrogen. The FLAG-c-Raf CRD protein was immunoprecipitated using anti-FLAG M2 affinity gel as
described above. The beads were resuspended in 25 µl of 10 mM dithiothreitol, 100 mM Tris, pH 8, and 0.5%
SDS and incubated at 42 °C for 1 h. Following reduction, 25 µl of 50 mM AMS, 100 mM Tris, pH 8, and 0.5%
SDS were added, and thiol trapping was allowed for 30 min at 37 °C
(48). The reaction was terminated by the addition of 10 µl of 4×
nonreducing Laemmli buffer and boiling for 5 min. The samples were
applied to a 16.5% Tris-Tricine SDS-PAGE gel from Bio-Rad and analyzed
by Western blot using monoclonal anti-FLAG M2 antibody (Sigma).
Bacteria Growth and Protein Purification--
The c-Raf-CRD was
expressed as GST fusion protein in the BL21/DE3 strain of
Escherichia coli (Novagen). The growth conditions were as
follows. The bacteria were initially grown at 37 °C to an optical
density at 600 nm of 0.5 and then transferred to room temperature. When
the optical density reached 0.7-0.8, protein synthesis was induced by
the addition of 0.5 mM
isopropyl- -D-thiogalactopyranoside, and the cells were
harvested 2 h later. Bacteria were lysed by two passages through a
French press, and the proteins were purified by affinity chromatography
on the glutathione-agarose matrix (Sigma) according to a standard
protocol. Purity by Coomassie Blue staining of SDS-PAGE was usually
>90% by this protocol.
Retinoid Binding Assay--
The fluorescence emission spectra of
250 nM GST-c-Raf CRD fusion protein, equimolar
concentrations of protein-retinoid complexes, and quantitative
fluorescence measurement of 250 nM protein with retinoid
titration at 25 nM increments, from a 75 µM
stock solution in methanol, were performed in PBS, purged of oxygen by
sparging with helium for 15 min in a JASCO spectrofluorimeter (model
FP777), as described in detail (41). The protein solution was excited at 280 nm, and the emission spectra were monitored from 300 to 550 nm,
or at 330 nm for the single wavelength measurements. All measurements
were repeated 4-6 times. Binding constants were calculated by
nonlinear curve fitting according to the theorem by Norris et
al. (49). Complementary binding data were obtained by the method
of enhancement of retinol fluorescence (41).
In Vivo Retinol Binding Assays--
COS-7 cells were transfected
with FLAG-c-Raf cDNA and cultured in retinol-free medium as
indicated above. Cells were preincubated with 100 nM
retinol, 14HRR, AR, RA, or phosphatidylserine for 15 min prior to the
addition of 5 nM [3H]retinol for 30 min and
harvested after washing with PBS containing 0.5% bovine albumin.
Extracts were prepared by repeated freeze thawing in 0.25 M
Tris, pH 8, supplemented with 25 µg/ml each leupeptin and aprotinin,
30 mM -glycerophosphate, 30 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 1 mM
vanadate. c-Raf immunoprecipitates were washed extensively with PBS
containing 0.5 M NaCl and 0.5% bovine albumin, and
incorporated counts were measured by liquid scintillation counting.
Results were expressed as differentials between immunoprecipitates of
transfected and nontransfected cultures.
Zinc Release Assay--
A solution of 250 nM of
GST-c-Raf CRD fusion protein in PBS was UV-irradiated at 312 nm for 2 min in the absence or presence of an equimolar concentration of
retinol, AR, or retinol plus AR, followed by the addition of 3 µM TSQ. The changes in the fluorescence emission spectrum
of TSQ (excitation max = 335 nm) were monitored from
390-600 nm.
 |
RESULTS |
Retinoids Bind the c-Raf CRD in Vitro--
Two spectrofluorimetric
methods, state of the art in the field (41, 49), were employed to
measure binding of retinoids to the c-Raf CRD: quenching and
enhancement. Quenching is based on the decrease in the intrinsic
protein fluorescence due to resonance energy transfer to a suitable
bound ligand. Fluorescence emanated from the natural Trp-186 residue.
Preliminary evidence3
suggested that retinol bound nearby at the second zinc chelation center
formed by Cys residues 165, 168, and 184, in cooperation with His-139.
Enhancement, or increase in the intrinsic fluorescence of the
ligand/retinoids, is predicated on the movement of the ligated
retinoids from the aqueous phase to the hydrophobic environment of the
receptor/CRD protein.
We have previously shown that retinol bound c-Raf and certain PKC CRDs
with nanomolar affinity (41). To test for binding of other natural
retinol metabolites, solutions of bacterially expressed GST-c-Raf-CRD
fusion protein were excited at 280 nm, and the changes in protein
fluorescence emission spectra were recorded, brought about by the
additions of stoichiometric amounts of retinoids. As illustrated in
Fig. 1A, the fluorescence
intensity of c-Raf CRD decreased in the presence of 14HRR, AR, or RA,
indicating binding. The signal was particularly prominent for 14HRR,
followed by AR, and moderately decreased by RA. In distinction from
retinol, no detectable fluorescence resonance energy transfer signal
was generated by the last three retinoids, probably due to their poor fluorescence properties.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
A, quenching of GST-c-Raf CRD intrinsic
fluorescence by retinoids. Shown are fluorescence emission spectra of a
250 nM solution of GST fusion protein comprising amino
acids 136-195 of human c-Raf excited at 280 nm in the absence or
presence of 250 nM 14HRR, AR, or RA in PBS and the spectra
of free 14HRR, AR, and RA in PBS. B, enhancement of the
fluorescence emission of retinoids bound to GST c-Raf CRD. The
fluorescence emission spectra of retinol, 14HRR, and AR are shown in
complex with stoichiometric amounts (250 nM) of the
GST-c-Raf CRD fusion protein, comprising amino acids 136-195, as well
as the fusion protein alone and free retinoids: retinol, 14HRR, and AR.
The excitations for retinol, 14HRR, and AR were 325, 348, and 368 nm,
respectively.
|
|
Binding of the retinoids, retinol, 14HRR, and AR, to the c-Raf CRD was
confirmed by the fluorescence enhancement method. Fig. 1B
shows the idiosyncratic increases in the emission spectrum intensities
that each retinoid produced when ligated to an equimolar amount of
c-Raf CRD. The magnitude of the enhancement differed for each retinoid,
reflecting the differences in their chromophore properties. RA, a
poorly fluorescent retinoid, could not be evaluated by this method.
To determine the binding constants, titrations of retinol, 14HRR, AR,
and RA were performed (Fig. 2). c-Raf CRD
(250 nM) was excited at 280 nm, and its fluorescence
emission was monitored at 330 nm after the addition of each 25 nM increment of retinoid from a 75 µM stock
solution in methanol. The binding curves, corrected for inner
filtering, indicated that binding was saturable. When applied to a
nonlinear curve fitting theorem developed by Norris et al.
(49), the apparent dissociation constants in the nanomolar range
were computed (Table I). Titration using
GST as specificity control yielded a flat line (data not shown), no
binding having taken place. Together, the results demonstrate high
affinity binding of the retinoids to the CRD in vitro.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 2.
Retinoid binding to the GST-c-Raf CRD is
quantitative. 250 nM solutions of GST-c-Raf CRD in PBS
were titrated with all-trans-retinol ( ), 14HRR ( ), AR
( ), and parinaric acid (PA) ( ) used as negative
control, added in 25 nM increments from a 75 µM stock solution in methanol. The protein solutions were
excited at 280 nM, and the changes in the protein's
fluorescence emission were monitored at the protein max
330 nm. The fluorescence intensity reading were corrected for inner
filtering and plotted versus retinoid concentrations.
|
|
Retinoids Bind c-Raf in Vivo--
Retinol has been shown to bind
c-Raf in vivo (41). To demonstrate binding of other
retinoids as well, a competition assay was developed, using COS-7 cell
transfectants expressing the full-length FLAG-c-Raf protein. Cells were
labeled with 5 nM [3H]retinol in the presence
or absence of 1 × 10 7 M retinol, 14HRR,
AR, and RA as cold competitors, and bound radioactivity was measured in
c-Raf immunoprecipitates using anti-FLAG antibody. All retinoids tested
competed for binding of [3H]retinol to c-Raf,
demonstrating specific binding (Fig. 3).
Phosphatidylserine, a known ligand of the c-Raf CRD, competed only
moderately with retinol, indicating minor overlap of binding sites
(27-29). Thus, the in vivo and in vitro binding
results established that the c-Raf CRD harbors a receptor site with
equal specificity for four retinoids tested, extending our previous
findings (41, 42).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Retinoids compete for binding to c-Raf
in vivo. COS cells expressing FLAG-tagged c-Raf
were pretreated for 15 min with 100 nM of unlabeled
retinol, 14HRR, AR, RA, or phosphatidylserine (PS), followed
by incubation for 30 min with 5 nM
[3H]retinol. Values for incorporated counts of the
immunoprecipitates, generated with agarose-conjugated anti-FLAG
antibody, were corrected for the radioactivity in control
immunoprecipitates of nontransfected cells (n = 4).
|
|
Retinoids Modulate c-Raf Activation by UV--
Having demonstrated
binding of retinoids to the CRD of c-Raf in vitro and
in vivo, it was important to inquire into the functional significance. Because UV irradiation activated c-Raf kinase capacity by
an oxidative mechanism and because retinol had emerged as pro-oxidant regulator (41, 42), we tested whether retinoids served as cofactors in
UV activation, using FLAG-c-Raf expressed to a high level in COS-7
cells. The results of c-Raf immunoprecipitation/kinase assays showed
that retinoids indeed modulated the UV responses in a
dose-dependent fashion, affecting the magnitude of kinase activation (Fig. 4) but not the kinetics
(as published previously (41)). When compared with retinoid-deprived
cultures, retinol and 14HRR at 1 µM were found to produce
an increase in phosphotransfer to disabled MEK, which peaked at 10 min
(3.7-fold increase (p = 0.004, n = 4)
and 2.3-fold increase (p = 0.085, n = 3), respectively). In contrast, AR and RA at 1 µM
produced decreases in FLAG-c-Raf kinase activity (1.8-fold decrease
(p = 0.019, n = 3) and 13.6-fold decrease (p = 0.003, n = 3),
respectively). On their own, retinoids had no discernible effect on
kinase activity. Thus, the retinol metabolites tested showed opposite
effects on c-Raf kinase activation mediated by UV-irradiation; retinol
and 14HRR enhanced while RA and AR antagonized the activity. Vitamin E,
a known antioxidant, had no effect on UV-mediated c-Raf kinase activity
(data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 4.
Retinoids regulate the UV activation of
c-Raf. Retinoids-depleted FLAG-c-Raf transfected COS cells were
reconstituted with the indicated concentrations of retinoids for 30 min
or left retinoid free. The cells were UV-irradiated, and 10 min later,
c-Raf activity was determined using disabled His-MEK as the substrate
in anti-FLAG-c-Raf immunoprecipitate/kinase assays. Transfection
efficiency was determined by c-Raf Western blot. A,
autoradiograph and Western blot of samples treated with retinol.
B, autoradiograph and Western blot of cultures treated with
14HRR. C, means ± S.E. and p values of
densitometric determinations of c-Raf kinase activities normalized for
amount of FLAG-c-Raf protein (n = 4 for retinol-treated
cells, n = 3 for 14HRR-treated cells). D,
autoradiograph and Western blots of cultures treated with AR.
E, autoradiograph and Western blot of cultures treated with
RA. F, means ± S.E. and p values of
densitometric determinations of c-Raf kinase activities normalized for
amount of FLAG-c-Raf protein (n = 3 for AR- and
RA-treated cultures) (**, compared with untreated cells; *, compared
with UV irradiated cells).
|
|
The Retinoids Are Functional Antagonists--
Retinoids bound the
c-Raf CRD equally well in vitro and competed for binding
in vivo but had opposite effects on survival of cells
(38-40, 50). Because these effects were at least partially attributable to c-Raf kinase regulation in vivo (41), we
tested whether retinol and AR would behave as functional antagonists in
c-Raf kinase assays. As shown in Fig. 5,
the inhibitory effect of AR on retinol, when used at equimolar
concentrations, was evident. These results indicate that the retinoids
compete for binding to c-Raf and act as functional antagonists.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
Retinol and AR are functional
antagonists. A, retinoid-depleted
FLAG-c-Raf-transfected COS cells were preincubated in the presence or
absence of 1 µM AR for 15 min, followed by the addition
of 1 µM retinol for 30 min, or left retinoid-free. The
cells were UV-irradiated, and 10 min later, c-Raf activity was
determined in anti-FLAG-c-Raf immunoprecipitate/kinase assays. PMA was
used as positive control at 100 ng/ml. Transfection efficiency was
determined by c-Raf Western blot. B, means ± S.E. of
densitometric determinations of c-Raf kinase activities normalized for
the amount of FLAG-c-Raf protein expression (n = 2).
|
|
UV Activation of c-Raf Is Not Reversible by Reduction--
UV
irradiation generates ROS (51-53). At low levels, these radicals are
not only tolerated by cells but are important for normal signal
transduction (33, 34). Since the hallmark of physiological activating
signals is their reversibility, we investigated whether UV activation
of c-Raf was abrogated by reducing agents. Fig. 6 illustrates 67% inhibition of c-Raf
activation by the addition of L-N-acetylcysteine
(NAC) at the time of UV stimulation followed by incubation for 10 min
(compare lane 3 with lane
5). However, once fully activated for 10 or 15 min, c-Raf
could no longer be influenced by the addition of 1 mM NAC
for 1 min (compare lane 3 with lane
6, and compare lane 4 with
lane 7), indicating that a complex mechanism
controlled the down-regulation of the kinase activity, requiring more
than a simple increase in the intracellular reducing power of the cell.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
UV activation of c-Raf is inhibited but not
reversed by NAC. The UV activation of c-Raf was inhibited by 1 mM NAC when added at the time of activation
(lanes 3 and 5) but not when added to
the fully active kinase for 1 min, as demonstrated by the addition of
NAC 10 or 15 min postactivation (lanes 6 and
7, respectively). At 10 min, c-Raf reached maximal kinase
function as demonstrated in kinetic studies (41).
|
|
UV Irradiation Directly Affects c-Raf in Vivo via Oxidation by
ROS--
To test whether ROS generated during UV stimulation had a
direct effect on c-Raf in vivo, we used the thiol-binding
probe AMS to test for the modification of thiol groups (47, 54). This assay is predicated on the alkylation of free thiol groups, but
not cysteine residues, by iodoacetamide. Reduction of disulfide, generated during UV/ROS exposure, restores free thiol groups that are
now available for reaction with AMS. Each bound AMS residue theoretically increases the molecular mass of the protein by 490 daltons. The altered size of FLAG-c-Raf CRD protein was assessed by
electrophoresis in SDS-PAGE under nonreducing conditions, although conformational changes could also contribute. The product of
UV-irradiated cells migrated significantly more slowly, consistent with
AMS modifications of the thiol groups, compared with the reference protein from untreated cells (Fig.
7A). Oxidation of cells by two
different concentrations of hydrogen peroxide caused the appearance of
two differently migrating bands, the slower of which represented the
higher degree of oxidation with the relatively larger number of
disulfide groups that, after the in vitro reduction, were
trapped by AMS.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 7.
UV irradiation has a direct effect on c-Raf
in vitro and in vivo.
A, the direct effect of UV and
H2O2 on c-Raf CRD was investigated in vivo
using AMS as thiol-trapping probe (47). The effect of AMS conjugation
on CRD was analyzed by Western blot on a 16.5% SDS-PAGE under
nonreducing conditions. B, UV-induced release of
Zn2+ from the c-Raf CRD was monitored by changes in TSQ
fluorescence in vitro. UV irradiation caused
Zn2+ release, and this release (dotted line) was
enhanced in the presence of retinol (thick short-dashed
line) and inhibited in the presence of AR (thick
dashed and dotted line). The
retinol-mediated Zn2+ release was antagonized by AR
(solid line).
|
|
UV Irradiation of c-Raf CRD Results in Zinc Release--
The c-Raf
CRD comprises two zinc-coordinated centers, one of which is formed by
the three thiol groups of Cys-165, Cys-168, and Cys-184 and one imino
group of His-139, whereas the other is formed by Cys-152, Cys-155,
Cys-176, and His-172. Because thiol groups were modified following UV
irradiation, we predicted that Zn2+ would be released.
Furthermore, we investigated to what extent retinoids might modulate
the UV-mediated oxidation and zinc release from the c-Raf CRD. Fig.
7B illustrates that the c-Raf-CRD fusion protein indeed shed
its zinc upon UV irradiation, as determined by the binding of liberated
zinc to TSQ, a zinc-sensitive fluorescent probe, in agreement with
recent in vivo
observations.3 In the
presence of retinol, the fluorescence emission of TSQ was significantly
enhanced, indicating that at similar ROS output, additional zinc
nevertheless was released. By contrast, AR inhibited UV-mediated
release of zinc ions from the c-Raf CRD. These results are consistent
with the postulated function of retinoids as redox regulators. They
strengthen the idea that the CRD represents the primary target of UV
irradiation and oxidation.2 The hierarchy of in
vitro effects of retinoids paralleled those seen in
vivo precisely. These results for the first time also imply a
central role of zinc ions in the regulation of c-Raf kinase.
The c-Raf CRD Is Essential for c-Raf Function--
c-Raf shares
the structural CRD motif with members of the PKC family (21).
Furthermore, the homologous domains in the PKC family bearing the
diacylglycerol and phorbol ester binding sites have been implicated in
the redox regulation of kinase function but do not promote interaction
with Ras. To investigate whether these domains are functionally
interchangeable, we replaced the c-Raf CRD domain with the PKC C1B
domain. COS-7 cells, transfected with wild type FLAG-c-Raf or the
FLAG-tagged chimeric c-Raf/PKC construct, were treated with UV
irradiation, serum, or PMA 2 days post-transfection. The data in Fig.
8 demonstrate that swapping the CRDs
inhibited c-Raf activity in response to UV by 76%
(p = 0.1, n = 3) and serum by 61%
(p = 0.1, n = 3). In contrast, the PMA
response was augmented 2-fold for the chimeric compared with wild type
c-Raf (p = 0.02, n = 3). The inability
of the chimera to respond to UV irradiation suggested that the c-Raf
CRD was essential for c-Raf function not only in mediating the
important Ras/c-Raf interaction but also as primary sensor of UV signal transmission. On the other hand, the enhanced responsiveness to PMA may
be explained by Ras-independent c-Raf activation due to the fact that
PMA binding to the CRD facilitated localization at the plasma membrane
(55), in analogy to the well studied paradigm governing PKC
cytosol-to-membrane translocation and activation (23).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 8.
The c-Raf CRD is essential for kinase
function. FLAG-c-Raf wild type and FLAG-c-Raf chimera with the
c-Raf CRD substituted for the PKC C1B domain were activated by UV
irradiation, serum (5% fetal calf serum), or phorbol ester (100 ng/ml
PMA). The wild type responded to the stimuli, but the chimera, being
unable to interact with Ras, did not respond to UV or serum.
Ras-independent membrane targeting and activation may explain the
effect of PMA on the chimera (55).
|
|
UV Activation of c-Raf Is Dependent on Ras/c-Raf
Interaction--
Growth factor-mediated activation of c-Raf is
dependent on Ras/c-Raf interaction (16). It was therefore of interest
to determine whether c-Raf activation by UV also required interaction
with Ras. To address this question, the N17-Ras mutant (56) was used as
a dominant negative element in FLAG-c-Raf cotransfection experiments in
COS-7 cells. Fig. 9A shows the
level of c-Raf kinase activity stimulated by UV in comparison with
serum and PMA. The presence of the N17-Ras dominant-negative mutant
caused a 66% reduction in the UV-mediated c-Raf activation
(p = 0.007, n = 3), suggesting mandatory interaction with GTP-Ras, like receptor protein-tyrosine kinase-mediated c-Raf activation. Inhibition by 38% (p = 0.09, n = 3) of PMA-induced c-Raf activation in the
presence of N17-Ras indicated the existence of a Ras- independent
pathway, as previously documented by Marais et al. (57). UV
activation, however, followed the classical, Ras-dependent
pathway.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 9.
UV activation of c-Raf is
Ras-dependent. The N17-Ras dominant-negative mutant
was overexpressed (A). Alternatively, the endogenous Ras
molecule was disabled by treatment with 3 mM perillic acid
in FLAG-c-Raf transfected COS cells (B). The cells were
activated by UV, UV plus 1 µM retinol, serum (5% fetal
calf serum), or PMA (100 ng/ml), and the activity of FLAG-c-Raf was
determined by immunoprecipitate/kinase assays. For further details, see
the legend to Fig. 4.
|
|
This conclusion was confirmed independently using a pharmacological
inhibitor of Ras post-translation modification. Perillic acid inhibits
cysteine isoprenylation, without which Ras cannot localize to the
plasma membrane and remains inoperative (58). Pretreatment of COS-7
cells for 12 h with 3 mM perillic acid resulted in
80% inhibition of UV-mediated FLAG-c-Raf kinase activation (Fig.
9B). These results are in agreement with those obtained by
the Ras dominant-negative mutant. Taken together, they indicate that the Ras/c-Raf interaction was absolutely required not only for
activation of c-Raf by growth factor but also by UV irradiation.
Tyrosine Phosphorylation and Serine or Threonine Dephosphorylation
Are Essential for c-Raf Optimal UV Activation--
Phosphorylation of
tyrosine residues Tyr-340 and Tyr-341 is essential for c-Raf
activation, one of the kinases responsible being a member of the Src
family (59, 60). To evaluate the role of Src kinases in the c-Raf
activation by UV, herbimycin A, a potent Src inhibitor, was used (61,
62). COS-7 transfectants were treated with 3 µM
herbimycin A for 30 min prior to stimulation. Fig.
10 shows that the activation of c-Raf
mediated by UV is decreased by 47% (p = 0.1, n = 2) and that of serum is decreased by 71% (p = 0.09, n = 2) (compare
lane 2 with lane 4, and
compare lane 3 with lane 5)
in herbimycin A-pretreated cultures, indicating that UV stimulation
does not bypass the requirement for c-Raf tyrosine phosphorylation.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 10.
Tyrosine phosphorylation and
serine/threonine dephosphorylation are necessary for the optimal
activation of c-Raf by UV irradiation. COS cells transfected with
FLAG-c-Raf were treated in the absence or presence of 3 µM herbimycin A, 100 nM okadaic acid, or 1 mM vanadate for 30 min prior to stimulation by UV
irradiation and serum (5% fetal calf serum). The activity of
FLAG-c-Raf was determined by immunoprecipitate/kinase assays and
Western blotting.
|
|
Tyrosine kinases are an essential component of c-Raf activation.
Omnipresent protein-tyrosine phosphatases counteract tyrosine phosphorylation. Hence, their inhibition may result in the constitutive activation of c-Raf. Since phosphatases are known to be deactivated by
ROS (63, 65), as demonstrated especially for protein-tyrosine phosphatase 1B with its ROS-sensitive cysteine in the catalytic domain
(66), it was necessary to demonstrate UV activation in cells in which
protein-tyrosine phosphatases were blocked by pharmacological inhibitors. FLAG-c-Raf-transfected COS-7 cells were therefore UV-irradiated in the presence of 1 mM sodium vanadate, a
specific inhibitor of tyrosine phosphatases. Fig. 10 shows that UV
irradiation caused a 20% increase in c-Raf activation in
vanadate-treated cells (p = 0.1, n = 3)
(compare lane 8 with lane
9); vanadate alone increased c-Raf basal activity (compare
lane 1 with lane 8). The
fact that UV caused an additive effect over that of vanadate alone
suggests that UV/ROS impacts on c-Raf directly.
To determine the influence of serine/threonine phosphatases on c-Raf
activation, we treated FLAG-c-Raf-transfected COS-7 cells with 100 nM okadaic acid (67, 68) for 30 min prior to stimulation by
UV. The presence of okadaic acid caused a 67% decrease in UV-mediated c-Raf activation (p = 0.01, n = 3)
(Fig. 10, compare lane 2 with lane
6); okadaic acid alone caused a negligible increase in c-Raf basal activity (data not shown). These data indicate the importance of
an okadaic acid-sensitive phosphatase, most likely protein phosphatase
2A, since this has been shown to form complexes with c-Raf in
vitro and in vivo (18) during the activation of c-Raf kinase. Taken together, the data indicate that the direct chemical effect of UV irradiation on the molecule was not sufficient for c-Raf
activation and did not bypass the requirements for Ras as well as
tyrosine kinases and phosphatases, well known for their obligatory
roles in growth factor and cytokine-mediated activation.
 |
DISCUSSION |
To understand the role of retinoids as regulators of c-Raf
function, we pursued four seemingly separate lines of experimentation. When integrated, however, our results offer a new perspective on the
function of the CRD, a subdomain of the N-terminal regulatory domain
that was long suspected to play a crucial role in kinase activation.
First, our previous finding that retinol bound the CRD was expanded to
14HRR, RA, and AR. These retinoids bound at the same site as retinol
with nanomolar affinity, precisely replicating the findings with
certain PKC CRDs (42). While they share the same -ionone ring and
polyene structure that presumably furnish the contact surface,
they differ in the functional groups at their tail ends. The presence
or absence of hydroxyls dictated biological function, as retinol
and 14HRR acted as agonists, whereas AR that lacks hydroxyl groups was
antagonistic (37-40, 50, 69-71). Complementing the in
vitro binding studies (Figs. 1 and 2 and Table I), we also furnish
evidence for binding in intact cells and provide at least qualitative
evidence that all four had affinity for full-length c-Raf in native
conformation (Fig. 3). Since retinol and 14HRR are nearly ubiquitous in
tissues at concentrations (2 × 10 6 and 1 × 10 7 M, respectively) exceeding the
Kd of the CRD-retinoid complex (2 × 108 mol 1), one can safely assume that inside
cells c-Raf is always loaded with retinoids.
It has long been recognized that UV irradiation and the ROS this
engenders lead to activation of a number of signal pathways (32, 36,
72). Prominent among these is the c-Raf/MAPK axis that plays a role in
physiological responses to UVB, for instance in skin cells (73-76). We
used UVB irradiation of cells as a quasipharmacological, convenient
mode of activation, since production of the actual mediator of kinase
activation, ROS, is restricted to the light period. The consequences
for c-Raf were then determined free of concern that continued exposure
to ROS might accumulate damage, as might be the case with most
oxidizing chemicals. Brief irradiation of cells initiated events that
peaked 10 min later in the expression of substantial c-Raf
phosphotransferase activity, determined in immunoprecipitates by
phosphorylation of the disabled substrate, MEK. The presence of retinol
promoted a substantial increase in kinase activity, confirming previous
findings that peroxide-mediated activation of c-Raf and PKC was
facilitated by bound retinol (41, 42). Extending the studies to natural
retinol metabolites, it was observed that 14HRR, as predicted from its
agonistic properties in cell survival assays (50, 70), also enhanced
UV-triggered c-Raf kinase activation, whereas AR did not (37-40, 69).
The latter effect mirrored the physiological consequence of growth inhibition and apoptosis that cells experience when exposed to AR. We
have provided evidence elsewhere that AR displaced retinol from the
common receptors and thus mimicked a state of retinol deficiency,
leading to growth retardation and apoptosis (37-40, 69). Similar
physiological effects are not uncommon with cultures depleted of
vitamin A (38, 50, 70). That retinol and AR acted as pharmacologic
mutual inhibitors was also evident in the UV activation experiments
(Fig. 5).
Since UV irradiation led to production of ROS, held responsible for the
initiation of the c-Raf activation cycle, it was desirable to show
direct chemical modifications of c-Raf. This was all the more
necessary, since ROS reportedly activates protein-tyrosine kinase
receptors (77-81), tyrosine kinases (14, 82, 83), and Ras (84, 85),
but inactivates phosphatases (66, 86). These signal transduction
molecules act to different degrees as upstream modulators of c-Raf,
confounding the issue. However, the following observations indicate
that c-Raf was indeed a direct target of ROS. First, ROS scavengers
prevented c-Raf activation (Fig. 6). Second, analysis of the thiol
content indicated distinct changes after UV irradiation of cells (Fig.
7A). The lowest number of thiol groups was found in peroxide
treated cells, under conditions that promoted kinase activation.
UV-induced changes could not be further assigned to specific cysteines
due to the complexity of the molecule. Third, oxidation of cysteines in
the CRD appeared the most likely scenario, in analogy to other
CRD-containing enzymes, such as PKC , 2, , and (43), and
the bacterial chaperone Hsp33 (48, 87). Oxidizing even one cysteine
residue ought to compromise the chelation of Zn2+. Indeed,
both Hsp33 and PKC set free their Zn2+ ions under
oxidizing conditions, and so did c-Raf (see below).
In the case of the Hsp33 chaperone, increased enzymatic capacity was
directly attributed to a controlled unfolding of the molecules, and
since this process was reversible by reduction, it was proposed that
zinc fingers served as redox-sensitive hinges (48). Activated c-Raf did
not revert to the inactive form by reduction with
N-acetylcysteine, in contrast to PKC, where repeated oxidation/reduction cycles turned kinase activity on or off (42). The
c-Raf CRD might therefore not obey the same paradigm of a reversible
redox switch. On the other hand, early events in the activation cycle
might depend on oxidative opening of the molecule, whereas the
secondary modifications that c-Raf experiences by interaction with
GTP/Ras might lock the kinase into an active conformation inured to
reducing conditions.
Using the reductionist approach, we determined that ROS, generated by
UV irradiation in vitro under the same conditions as in vivo, was capable of causing the rapid release
of Zn2+ ions from the GST-c-Raf CRD fusion protein. We
quote this observation as the fourth argument for direct effects on
c-Raf. Although GST fusion proteins were not ideal tools to study
protein function because of an inherent uncertainty of how well
bacteria mastered folding mammalian peptides into their proper
configuration, our results represent a credible in vitro
correlate to the functional activation studies in
vivo. This correlation was strengthened by the finding that
GST-Raf fusion protein permitted substantially higher Zn2+
ion release when loaded with equimolar retinol. Conversely, AR suppressed Zn2+ release, whereas the equimolar mixture of
retinol and AR behaved like retinoid-free protein (Fig. 7A).
Thus, the biology of retinoids was mirrored by their biophysical
effects on the isolated CRD.
The importance of the CRD for regulation of c-Raf kinase has been
widely documented. Major contact sites enabling communication with
GTP/Ras are embedded in this domain. The classical pathway, initiated
by receptor phosphotyrosine kinases, is dependent on complex formation
with Ras at the membrane. The alternate, redox-dependent pathway follows a similar route. First, redox activation of c-Raf required the presence of a CRD competent in Ras recognition.
Substituting the PKC CIB CRD for the c-Raf CRD abolished its
activation by UV irradiation but shunted this chimeric kinase to the
PKC pathway, similar to results described by Avruch and colleagues
(55), since it became highly responsive to phorbol ester (Fig. 8).
Second, competitive inhibition of the Raf/Ras interaction by
overexpression of mutant N17-Ras was another indication of dependence
on Ras. After modification by ROS, generated during UV irradiation,
presumably involving oxidation of cysteine residues of the CRD,
relocation of Zn2+ ions, and consequent conformational
change, the interaction with GTP/Ras was still required. Furthermore,
preventing prenylation and insertion of Ras into the membrane curtailed
UV activation of c-Raf.
Our studies re-emphasize the importance of agonistic retinoids for
controlled activation of the c-Raf/MAPK by oxidizing agents. They also
illuminate the role of zinc as an essential dynamic component of c-Raf.
Both, control by retinol and zinc, converge on the same domain in the
kinase. It is interesting to note that nutritional vitamin A and zinc
deficiency produce many of the same symptoms: night blindness,
sterility, defective wound healing, and abnormal skin regeneration.
More research is needed to understand whether the underlying common
parameter involves the CRD of c-Raf and related serine/threonine
kinases. In distinction from its role as catalytic center in numerous
enzymes, zinc occurs as a structural component in dozens of cytoplasmic
and nuclear proteins including, notably, signal transduction molecules
and transcription factors. Although "zinc fingers" are commonly
thought of as rigid structures that enable in the case of transcription
factors the intercalation into the DNA double helix, their role in the
newly emerging redox regulation is apt to change our perception. The zinc fingers should be viewed as redox-regulated, dynamic, and reversible hinges, as proposed for the bacterial chaperone, Hsp33. Another view is that they act as redox sensors with provisions in
mammalian cells for fine-tuning by different retinoids. Such a control
element would allow c-Raf and its homologues to make constant
adjustments in enzymatic output, as dictated by the changing redox
status of cells.
 |
FOOTNOTES |
*
This work was supported by the National Institutes of Health
Grants CA 89362S1 (to B. H.) and CA 49933 (to U. H.), National Cancer
Institute Training Grant CA T32 09149 (to A. I.), and American Heart
Association Grant 003039T (to I. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Immunology Program,
Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY
10021. Tel.: 212-639-7523; Fax: 212-794-4019; E-mail: u-hammerling@ski.mskcc.org.
Published, JBC Papers in Press, April 23, 2002, DOI 10.1074/jbc.M110750200
2
I. Korichneva, unpublished data.
3
B. Hoyos, unpublished observation.
 |
ABBREVIATIONS |
The abbreviations used are:
MAPK, mitogen-activated protein kinase;
14HRR, 14-hydroxyretroretinol;
AR, anhydroretinol;
RA, retinoic acid;
CRD, cysteine-rich domain(s);
ROS, reactive oxygen species;
PKC, protein kinase C;
TSQ, N-(6-methoxy-8-quinolyl)-p-toluene sulfonamide;
AMS, 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid;
GST, glutathione S-transferase;
PBS, phosphate-buffered saline;
NAC, L-N-acetylcysteine;
Hsp33, heat shock
protein 33;
PMA, phorbol 12-myristate 13-acetate;
MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase;
Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
 |
REFERENCES |
| 1.
|
Howe, L. R.,
Leevers, S. J.,
Gomez, N.,
Nakielny, S.,
Cohen, P.,
and Marshall, C. J.
(1992)
Cell
71,
335-342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Marais, R.,
and Marshall, C. J.
(1996)
Cancer Surv.
27,
101-125[Medline]
[Order article via Infotrieve]
|
| 3.
|
Habelhah, H.,
Shah, K.,
Huang, L.,
Ostareck-Lederer, A.,
Burlingame, A. L.,
Shokat, K. M.,
Hentze, M. W.,
and Ronai, Z.
(2001)
Nat. Cell Biol.
3,
325-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sano, H.,
Zhu, X.,
Sano, A.,
Boetticher, E. E.,
Shioya, T.,
Jacobs, B.,
Munoz, N. M.,
and Leff, A. R.
(2001)
J. Immunol.
166,
3515-3521[Abstract/Free Full Text]
|
| 5.
|
Dufresne, S. D.,
Bjorbaek, C., El-,
Haschimi, K.,
Zhao, Y.,
Aschenback, W. G.,
Moller, D. E.,
and Goodyear, L. J.
(2001)
Mol. Cell. Biol.
21,
81-87[Abstract/Free Full Text]
|
| 6.
|
Yordy, J. S.,
and Muise-Helmericks, R. C.
(2000)
Oncogene
19,
6503-6513[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Wang, Y.,
and Prywes, R.
(2000)
Oncogene
19,
1379-1385[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Chung, J.,
Uchida, E.,
Grammer, T. C.,
and Blenis, J.
(1997)
Mol. Cell. Biol.
17,
6508-6516[Abstract]
|
| 9.
|
Cruzalegui, F. H.,
Cano, E.,
and Treisman, R.
(1999)
Oncogene
18,
7948-7957[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Morrison, D. K.
(1995)
Mol. Reprod. Dev.
42,
507-514[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Morrison, D. K.,
and Cutler, R. E.
(1997)
Curr. Opin. Cell Biol.
9,
174-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Rapp, U. R.
(1991)
Oncogene
6,
495-500[Medline]
[Order article via Infotrieve]
|
| 13.
|
Radler-Pohl, A.,
Sachsenmaier, C.,
Gebel, S.,
Auer, H. P.,
Bruder, J. T.,
Rapp, U.,
Angel, P.,
Rahmsdorf, H. J.,
and Herrlich, H.
(1993)
EMBO J.
12,
1005-1012[Medline]
[Order article via Infotrieve]
|
| 14.
|
Devary, Y.,
Gottlieb, R. A.,
Smeal, T.,
and Karin, M.
(1992)
Cell
71,
1081-1091[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Kasid, U.,
Suy, S.,
Dent, P.,
Ray, S.,
Whiteside, T. L.,
and Sturgill, T. W.
(1996)
Nature
382,
813-816[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Marshall, M.
(1995)
Mol. Reprod. Dev.
42,
493-499[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Fabian, J. R.,
Daar, I. O.,
and Morrison, D. K.
(1993)
Mol. Cell Biol.
13,
7170-7179[Abstract/Free Full Text]
|
| 18.
|
Abraham, D.,
Podar, K.,
Pacher, M.,
Kubicek, M.,
Welzel, N.,
Hemmings, B. A.,
Dilworth, S. M.,
Mischak, H.,
Kolch, W.,
and Baccarini, M.
(2000)
J. Biol. Chem.
275,
22300-22304[Abstract/Free Full Text]
|
| 19.
|
Ghosh, S.,
and Bell, R. M.
(1994)
J. Biol. Chem.
269,
30785-30788[Abstract/Free Full Text]
|
| 20.
|
Daub, M.,
Jockel, J.,
Quack, T.,
Weber, C. K.,
Schmitz, F.,
Rapp, U. R.,
Wittinghofer, A.,
and Block, C.
(1998)
Mol. Cell. Biol.
18,
6698-6710[Abstract/Free Full Text]
|
| 21.
|
Hurley, J. H.,
Newton, A. C.,
Parker, P. J.,
Blumberg, P. M.,
and Nishizuka, Y.
(1997)
Protein Sci.
6,
477-480[Medline]
[Order article via Infotrieve]
|
| 22.
|
Mott, H. R.,
Carpenter, J. W.,
Zhong, S.,
Ghosh, S.,
Bell, R. M.,
and Campbell, S. L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8312-8317[Abstract/Free Full Text]
|
| 23.
|
Newton, A. C.
(1993)
Annu. Rev. Biophys. Biomol. Struct.
22,
1-25[Medline]
[Order article via Infotrieve]
|
| 24.
|
Bittova, L.,
Stahelin, R. V.,
and Chol, W.
(2001)
J. Biol. Chem.
276,
4218-4226[Abstract/Free Full Text]
|
| 25.
|
Johnson, J. E.,
Giorgione, J.,
and Newton, A. C.
(2000)
Biochemistry
39,
11360-11369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Kazanietz, M. G.,
Bachi, J. J. Jr.,
Omichinski, J. G.,
and Blumberg, P. M.
(1995)
J. Biol. Chem.
270,
14679-14684[Abstract/Free Full Text]
|
| 27.
|
Ghosh, S.,
Xie, W-Q.,
Quest, A. F. G.,
Mabrouk, G. M.,
Strum, J. C.,
and Bell, R. M.
(1994)
J. Biol. Chem.
269,
10000-10007[Abstract/Free Full Text]
|
| 28.
|
Ghosh, S.,
Strum, J. C.,
Sciorra, V. A.,
Daniel, L.,
and Bell, R. M.
(1996)
J. Biol. Chem.
271,
8472-8480[Abstract/Free Full Text]
|
| 29.
|
Improta-Brears, T.,
Ghosh, S.,
and Bell, R. M.
(1999)
Mol. Cell. Biochem.
198,
171-178[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Rizzo, M. A.,
Shome, K.,
Watkins, S. C.,
and Romero, G.
(2000)
J. Biol. Chem.
275,
23911-23918[Abstract/Free Full Text]
|
| 31.
|
Hildeman, D. A.,
Mitchell, T.,
Teague, T. K.,
Henson, P.,
Day, B. J.,
Kappler, J.,
and Marrack, P. C.
(1999)
Immunity
10,
735-744[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Lander, H. M.
(1997)
FASEB J.
11,
118-124[Abstract]
|
| 33.
|
Los, M.,
Droge, W.,
Stricker, K.,
Baeuerle, P. A.,
and Schulze-Osthoff, K.
(1995)
Eur. J. Immunol.
25,
159-165[Medline]
[Order article via Infotrieve]
|
| 34.
|
Goldstone, S. D.,
and Hunt, N. H.
(1997)
Biochim. Biophys. Acta
1355,
353-360[Medline]
[Order article via Infotrieve]
|
| 35.
|
Scharffetter-Kochanek, K.,
Wlaschek, M.,
Brenneisen, P.,
Schauen, M.,
Blaudschun, R.,
and Wenk, J.
(1997)
Biol. Chem.
378,
1247-1257[Medline]
[Order article via Infotrieve]
|
| 36.
|
Tyrrell, R. M.
(1996)
Bioessays
18,
139-148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Buck, J.,
Grun, F.,
Derguini, F.,
Chen, Y.,
Kimura, S.,
Noy, N.,
and Hammerling, U.
(1993)
J. Exp. Med.
178,
675-680[Abstract/Free Full Text]
|
| 38.
|
Chen, Y.,
Derguini, F.,
and Buck, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10205-10208[Abstract/Free Full Text]
|
| 39.
|
O'Connell, M. J.,
Chua, R.,
Hoyos, B.,
Buck, J.,
Chen, Y.,
Derguini, F.,
and Hammerling, U.
(1996)
J. Exp. Med.
184,
549-555[Abstract/Free Full Text]
|
| 40.
|
Korichneva, I.,
and Hammerling, U.
(1999)
J. Cell Sci.
112,
2521-2528[Abstract]
|
| 41.
|
Hoyos, B.,
Imam, A.,
Chua, R.,
Swenson, C.,
Tong, G. X.,
Levi, E.,
Noy, N.,
and Hammerling, U.
(2000)
J. Exp. Med.
192,
835-845[Abstract/Free Full Text]
|
| 42.
|
Imam, A.,
Hoyos, B.,
Swenson, C.,
Levi, E.,
Chua, R.,
Viriya, E.,
and Hammmerling, U.
(2001)
FASEB J.
15,
28-30[Free Full Text]
|
| 43.
|
Knapp, L. T.,
and Klann, E.
(2000)
J. Biol. Chem.
275,
24136-24145[Abstract/Free Full Text]
|
| 44.
|
Derguini, F.,
Nakanishi, K.,
Hammerling, U.,
and Buck, J.
(1994)
Biochemistry
33,
623-628[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Graham, F. L.,
and van der Eb, A. J.
(1973)
Virology
52,
456-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Bernier, M.,
Nadiv, O.,
and Kole, H. K.
(1995)
Biochemistry
34,
8357-8364[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Jakob, U.,
Muse, W.,
Eser, M.,
and Bardwell, J. C.
(1999)
Cell
96,
341-352[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Norris, A. W.,
Cheng, L.,
Giguere, V.,
Rosenberger, M.,
and Li, E.
(1994)
Biochim. Biophys. Acta
1209,
10-18[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Buck, J.,
Derguini, F.,
Levi, E.,
Nakanishi, K.,
and Hammerling, U.
(1991)
Science
254,
1654-1656[Abstract/Free Full Text]
|
| 51.
|
Yasui, H.,
and Sakurai, H.
(2000)
Biochem. Biophys. Res. Commun.
269,
131-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Chan, W. H.,
and Yu, J. S.
(2000)
J. Cell. Biochem.
78,
73-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Tobi, S. E.,
Paul, N.,
and McMillan, T. J.
(2000)
J. Photochem. Photobiol. B.
57,
102-112[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Joly, J. C.,
and Swartz, J. R.
(1997)
Biochemistry
36,
10067-10072[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Luo, Z.,
Diaz, B.,
Marshall, M. S.,
and Avruch, J.
(1997)
Mol. Cell. Biol.
17,
46-53[Abstract]
|
| 56.
|
Feig, L. A.,
and Cooper, G. M.
(1988)
Mol. Cell. Biol.
8,
3235-3243[Abstract/Free Full Text]
|
| 57.
|
Marais, R.,
Light, Y.,
Mason, C.,
Paterson, H.,
Olson, M. F.,
and Marshall, C. J.
(1998)
Science
280,
109-112[Abstract/Free Full Text]
|
| 58.
|
Huang, Y.,
and Rane, S. G.
(1994)
J. Biol. Chem.
269,
31183-31189[Abstract/Free Full Text]
|
| 59.
|
Mason, C. S.,
Springer, C. J.,
Cooper, R. G.,
Superti-Furga, G.,
Marshall, C. J.,
and Marais, R.
(1999)
EMBO J.
18,
2137-2148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Marais, R.,
Light, Y.,
Paterson, H. F.,
and Marshall, C. J.
(1995)
EMBO J.
14,
3136-3145[Medline]
[Order article via Infotrieve]
|
| 61.
|
Fukazawa, H.,
Uehara, Y.,
Murakami, Y.,
Mizuno, S.,
Hamada, M.,
and Takeuchi, T.
(1994)
FEBS Lett.
340,
155-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Murakami, Y.,
Mizuno, S.,
Hori, M.,
and Uehara, Y.
(1988)
Cancer Res.
48,
1587-1590[Abstract/Free Full Text]
|
| 63.
|
Dent, P.,
Jelinek, T.,
Morrison, D. K.,
Weber, M. J.,
and Sturgill, T. W.
(1995)
Science
268,
1902-1906[Abstract/Free Full Text]
|
| 64.
|
Xia, K.,
Lee, R. S.,
Narsimhan, R. P.,
Mukhopadhyay, N. K.,
Neel, B. G.,
and Roberts, T. M.
(1999)
Mol. Cell. Biol.
19,
4819-4824[Abstract/Free Full Text]
|
| 65.
|
Galaktionov, K.,
Jessus, C.,
and Beach, D.
(1995)
Genes Dev.
9,
1046-1058[Abstract/Free Full Text]
|
| 66.
|
Barrett, W. C.,
DeGnore, J. P.,
Keng, Y-F.,
Zhang, Z-Y.,
Yim, M. B.,
and Chock, P. B.
(1999)
J. Biol. Chem.
274,
34543-34546[Abstract/Free Full Text]
|
| 67.
|
Favre, B.,
Turowski, P.,
and Hemmings, B. A.
(1997)
J. Biol. Chem.
272,
13856-13863[Abstract/Free Full Text]
|
| 68.
|
Hunter, T.
(1995)
Cell
80,
225-236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Chen, Y.,
Buck, J.,
and Derguini, F.
(1999)
Cancer Res.
59,
3985-3990[Abstract/Free Full Text]
|
| 70.
|
Garbe, A.,
Buck, J.,
and Hammerling, U.
(1992)
J. Exp. Med.
176,
109-117[Abstract/Free Full Text]
|
| 71.
|
Derguini, F.,
Nakanishi, K.,
Hammerling, U.,
Chua, R.,
Eppinger, T.,
Levi, E.,
and Buck, J.
(1995)
J. Biol. Chem.
270,
18875-18880[Abstract/Free Full Text]
|
| 72.
|
Burdon, R. H.
(1995)
Free Radic. Biol. Med.
18,
775-794[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
Geilen, C. C.,
Wieprecht, M.,
and Orfanos, C. E.
(1996)
J. Dermatol. Sci.
12,
255-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 74.
|
Englaro, W.,
Derijard, B.,
Ortonne, J. P.,
and Ballotti, R.
(1998)
Oncogene
16,
661-664[CrossRef][Medline]
[Order article via Infotrieve]
|
| 75.
|
Kuhn, C.,
Hurwitz, S. A.,
Kumar, M. G.,
Cotton, J.,
and Spandau, D. F.
(1999)
Int. J. Cancer
80,
431-438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 76.
|
Peus, D.,
Vasa, R. A.,
Beyerle, A.,
Meves, A.,
Krautmacher, C.,
and Pittelkow, M. R.
(1999)
J. Invest. Dermatol.
112,
751-756[CrossRef][Medline]
[Order article via Infotrieve]
|
| 77.
|
Monteiro, H. P.,
and Stern, A.
(1996)
Free Radic. Biol. Med.
21,
323-333[CrossRef][Medline]
[Order article via Infotrieve]
|
| 78.
|
Schmid, E.,
Hotz-Wagenblatt, A.,
Hacj, V.,
and Droge, W.
(1999)
FASEB J.
13,
1491-1500[Abstract/Free Full Text]
|
| 79.
|
Garant, M. J.,
Kole, S.,
Maksimova, E. M.,
and Bernier, M.
(1999)
Biochemistry
38,
5896-5904[CrossRef][Medline]
[Order article via Infotrieve]
|
| 80.
|
Hirota, K.,
Murata, M.,
Itoh, T.,
Yodoi, J.,
and Fukuda, K.
(2001)
J. Biol. Chem.
276,
25953-25958[Abstract/Free Full Text]
|
| 81.
|
Iantomasi, T.,
Favilli, F.,
Catarzi, S.,
and Vincenzini, M. T.
(2001)
Biochem. Biophys. Res. Commun.
280,
1279-1285[CrossRef][Medline]
[Order article via Infotrieve]
|
| 82.
|
Pu, M.,
Akhand, A. A.,
Kato, M.,
Hamaguchi, M.,
Koike, T.,
Iwata, H.,
Sabe, H.,
Suzuki, H.,
and Nakashima, I.
(1996)
Oncogene
13,
2615-2622[Medline]
[Order article via Infotrieve]
|
| 83.
|
Abe, J.,
Takahashi, M.,
Ishida, M.,
Lee, J. D.,
and Berk, B. C.
(1997)
J. Biol. Chem.
272,
20389-20394[Abstract/Free Full Text]
|
| 84.
|
Lander, H. M.,
Milbank, A. J.,
Tauras, J. M.,
Hajjar, D. P.,
Hempstead, B. L.,
Schwartz, G. D.,
Kraemer, R. T.,
Mirza, U. A.,
Chait, B. T.,
Burk, S. C.,
and Quilliam, L. A.
(1996)
Nature
381,
380-381[CrossRef][Medline]
[Order article via Infotrieve]
|
| 85.
|
Deora, A. A.,
Hajjar, D. P.,
and Lander, H. M.
(2000)
Biochemistry
39,
9901-9908[CrossRef][Medline]
[Order article via Infotrieve]
|
| 86.
|
Cunnick, J. M.,
Dorsey, J. F.,
Mei, L.,
and Wu, J.
(1998)
Biochem. Mol. Biol. Int.
45,
887-894[Medline]
[Order article via Infotrieve]
|
| 87.
|
Jakob, U.,
Eser, M.,
and Bardwell, J. C.
(2000)
J. Biol. Chem.
275,
38302-38310[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H.-J. Chiu, D. A. Fischman, and U. Hammerling
Vitamin A depletion causes oxidative stress, mitochondrial dysfunction, and PARP-1-dependent energy deprivation
FASEB J,
November 1, 2008;
22(11):
3878 - 3887.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Y. Park, A. Dillard, E. A. Williams, E. T. Wilder, M. R. Pepper, and M. A. Lane
Retinol Inhibits the Growth of All-Trans-Retinoic Acid-Sensitive and All-Trans-Retinoic Acid-Resistant Colon Cancer Cells through a Retinoic Acid Receptor-Independent Mechanism
Cancer Res.,
November 1, 2005;
65(21):
9923 - 9933.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Beeram, A. Patnaik, and E. K. Rowinsky
Raf: A Strategic Target for Therapeutic Development Against Cancer
J. Clin. Oncol.,
September 20, 2005;
23(27):
6771 - 6790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Hoyos, S. Jiang, and U. Hammerling
Location and Functional Significance of Retinol-binding Sites on the Serine/Threonine Kinase, c-Raf
J. Biol. Chem.,
February 25, 2005;
280(8):
6872 - 6878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Spencer, M. Theodosiou, and D. J. Noonan
NPDC-1, a Novel Regulator of Neuronal Proliferation, Is Degraded by the Ubiquitin/Proteasome System through a PEST Degradation Motif
J. Biol. Chem.,
August 27, 2004;
279(35):
37069 - 37078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Jirakulaporn and A. J. Muslin
Cation Diffusion Facilitator Proteins Modulate Raf-1 Activity
J. Biol. Chem.,
June 25, 2004;
279(26):
27807 - 27815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. F. Graf, M. Martinez-Yamout, S. VanHaerents, H. Lilie, H. J. Dyson, and U. Jakob
Activation of the Redox-regulated Chaperone Hsp33 by Domain Unfolding
J. Biol. Chem.,
May 7, 2004;
279(19):
20529 - 20538.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-M. Go, J. J. Gipp, R. T. Mulcahy, and D. P. Jones
H2O2-dependent Activation of GCLC-ARE4 Reporter Occurs by Mitogen-activated Protein Kinase Pathways without Oxidation of Cellular Glutathione or Thioredoxin-1
J. Biol. Chem.,
February 13, 2004;
279(7):
5837 - 5845.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|